New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:43 EDTOPHTOphthotech initiates first expansion study of Fovista therapy
Ophthotech Corporation announced today the initiation of the first of several planned expansion trials, in addition to the ongoing Fovista combination therapy Phase 3 clinical program. These expansion trials will investigate the potential role of Fovista combination therapy in reducing sub-retinal fibrosis, addressing sub-optimal treatment response and reducing treatment burden in wet age-related macular degeneration patients receiving anti-vascular endothelial growth factor monotherapy. The first expansion trial is a Phase 2a open-label study investigating the potential role of anti-platelet derived growth factor therapy in combination with anti-VEGF therapy in reducing sub-retinal fibrosis in wet AMD patients. The company also announced that a subgroup analysis showing a reduction of sub-retinal fibrosis and neovascular growth in patients receiving Fovista and Lucentis in the company’s Phase 2b trial has been accepted as an oral presentation at this year’s Annual Meeting of the American Academy of Ophthalmology, one of the major medical meetings for retinal physicians.
News For OPHT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
07:33 EDTOPHTOphthotech names Michael Atieh as EVP, Chief Financial and Business Officer
Ophthotech Corporation (OPHT) announced that Michael G. Atieh has been named EVP, Chief Financial and Business Officer and Treasurer effective September 30. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the company of his intention to retire effective September 30. Atieh spent the majority of his career in the pharmaceutical industry with Merck and Co (MRK), where he held various senior level positions over a 20 year period including Senior Vice President-Merck Medco Managed Care, Vice President-U.S. Human Health, Vice President-Public Affairs, Vice President-Government Relations, and Treasurer.
September 16, 2014
07:32 EDTOPHTOphthotech announces Fovista Phase 2b trial presentation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use